Technical and Clinical Validity of Assessing Measurable Residual Disease by Multicolor Flow Cytometry in an Unselected Acute Myeloid Leukemia Patient Cohort
Our study provides data-driven technical insights for laboratories considering MFC AML MRD implementation and offers strong evidence supporting the utility of MRD assessment by MFC in patients with AML undergoing various stages of treatment and surveillance.
Authors
- Leonard Jeffrey Medeiros (ORCID: https://orcid.org/0000-0001-6577-8006)
- Farhad Ravandi (ORCID: https://orcid.org/0000-0002-7621-377X)
- Shimin Hu (ORCID: https://orcid.org/0000-0001-7110-3814)
- Beenu Thakral (ORCID: https://orcid.org/0000-0001-5140-3633)
- Jeffrey L. Jorgensen (ORCID: https://orcid.org/0000-0002-1875-2986)
- Chi Young Ok (ORCID: https://orcid.org/0000-0002-6822-7880)
- Sanam Loghavi (ORCID: https://orcid.org/0000-0001-8980-3202)
- Fuli Jia
- Sa A. Wang (ORCID: https://orcid.org/0000-0001-9385-9911)
- Nicholas James Short (ORCID: https://orcid.org/0000-0002-2983-2738)
- Wei J. Wang (ORCID: https://orcid.org/0000-0002-1957-3226)
- Jie Xu (ORCID: https://orcid.org/0000-0003-1014-3745)
- Shaoying Li (ORCID: https://orcid.org/0000-0002-6857-0523)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Archives of Pathology & Laboratory Medicine
- Published
- 2025-06-16
- DOI
- https://doi.org/10.5858/arpa.2025-0053-oa
- Citations
- 1
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77